Immune-Related Adverse Events: When the Immune System Overshoots

Which Organs Are Affected

Almost any organ can be involved. The most common are the skin (rash, itch), gut (colitis, diarrhoea), endocrine glands (thyroid dysfunction, hypophysitis, less often type 1 diabetes or adrenal insufficiency), liver (hepatitis) and lungs (pneumonitis). Rarer events affect the heart, nervous system, kidneys, joints and eyes.

Endocrine effects are often permanent, requiring lifelong hormone replacement, whereas inflammation of other organs usually resolves with treatment.

Timing and Risk Factors

Skin and gut events tend to appear within weeks; endocrine and lung events somewhat later; some occur months after stopping treatment. Combination CTLA-4 plus PD-1 therapy causes more frequent and more severe events than either agent alone, and higher CTLA-4 doses increase risk.

A pre-existing autoimmune condition raises the chance of a flare, though checkpoint inhibitors are not absolutely contraindicated in that situation.

General Management Principles

Published guidelines grade events by severity. Mild events are often managed with topical or symptomatic treatment while continuing therapy; moderate to severe events usually require holding the drug and starting corticosteroids, with additional immunosuppression for steroid-refractory cases.

Whether treatment can be restarted after a serious event depends on the organ involved and the severity. This is specialist management, and the details are individualised.

Do Side Effects Predict Response?

Several studies have found that patients who develop an immune-related adverse event, particularly skin or endocrine toxicity, are more likely to be responding to the checkpoint inhibitor, consistent with both effects stemming from a vigorously activated immune system. The association is not strong enough to use prognostically for an individual, and serious toxicity is harmful regardless of any link with benefit.

A practical consequence is that toxicity is managed to preserve the option of continuing or resuming treatment where safe: the lowest effective corticosteroid dose and course, early involvement of organ specialists, and rechallenge for many moderate events once they resolve. Short courses of high-dose steroids do not appear to negate the anti-tumour effect, though prolonged immunosuppression might.

Key Takeaways

• ·Immune-related adverse events are inflammatory attacks on normal organs caused by loss of immune restraint.
• ·Skin, gut, endocrine, liver and lung are most commonly affected; endocrine effects are often permanent.
• ·Combination checkpoint blockade increases the frequency and severity of these events.